What is the recommended treatment for intracranial atherosclerosis?

Treatment for Intracranial Atherosclerosis

For symptomatic intracranial atherosclerotic stenosis (ICAS), aggressive medical management with dual antiplatelet therapy (aspirin 325 mg/day plus clopidogrel 75 mg/day for 90 days, followed by aspirin monotherapy), high-intensity statin therapy targeting LDL <70 mg/dL, and blood pressure control <140/90 mmHg is the recommended first-line treatment; endovascular intervention should NOT be performed as initial therapy. 1, 2

Medical Management: The Cornerstone of Treatment

Antiplatelet Therapy

For symptomatic ICAS patients:

• Dual antiplatelet therapy is recommended for up to 90 days:
  • Aspirin 325 mg daily PLUS clopidogrel 75 mg daily 1, 2
  • This applies particularly to patients with severe stenosis (70-99%) and low hemorrhagic transformation risk 1
• After 90 days: transition to aspirin 325 mg daily as lifelong monotherapy 1

Important caveat: Warfarin is NOT recommended—the WASID trial demonstrated no benefit over aspirin with significantly higher rates of death (9.7% vs 4.3%), major hemorrhage (8.3% vs 3.2%), and myocardial infarction (7.3% vs 2.9%) 3

Aggressive Risk Factor Control

Lipid management:

• High-intensity statin therapy targeting LDL cholesterol <70 mg/dL (or <1.8 mmol/L) 1, 4

Blood pressure control:

• Long-term target: <140/90 mmHg 1, 4
• Critical caveat: Blood pressure must be managed cautiously in the acute/early stroke phase to avoid hypoperfusion 5

Glycemic control:

• Target HbA1c <7.0% in diabetic patients 4

Lifestyle modifications:

• At least moderate physical activity 1
• Smoking cessation, healthy diet 4

When NOT to Use Endovascular Therapy

Endovascular therapy (angioplasty/stenting) should NOT be recommended in the following scenarios:

1. As initial treatment for any degree of symptomatic ICAS 1, 2
2. Moderate stenosis (50-69%) at any time 1
3. Asymptomatic ICAS for primary stroke prevention 4
4. Direct or indirect bypass surgery is not recommended 1

The SAMMPRIS trial definitively showed that percutaneous transluminal angioplasty and stenting (PTAS) was inferior to aggressive medical management alone, with unacceptably high periprocedural stroke/death rates 1, 6.

Selective Role for Endovascular Intervention

Endovascular therapy may be considered ONLY in highly selected patients who:

• Have severe stenosis (70-99%)
• Have failed aggressive medical management (recurrent strokes despite optimal medical therapy)
• Demonstrate hemodynamic compromise or hypoperfusion 7, 4
• Are treated >21 days after the index stroke (not in acute phase) 4

Emerging evidence suggests:

• Submaximal balloon angioplasty (without stenting) may have lower procedural risk than stenting 6
• Drug-coated balloons and drug-eluting stents show promise for reducing restenosis 7, 6
• Strict patient selection and avoiding high-risk lesions (perforator-associated disease) improves outcomes 6

Special Consideration: Acute Large Vessel Occlusion Due to ICAS

For patients presenting with acute large vessel occlusion (LVO) caused by underlying ICAS during mechanical thrombectomy:

• Initial approach: Standard mechanical thrombectomy 8
• If thrombectomy fails or shows underlying ICAS: Consider escalation to:
  • Glycoprotein IIb-IIIa inhibitors 2
  • Rescue angioplasty/stenting for refractory cases 2, 8
• Immediate antiplatelet therapy should be initiated when ICAS is identified 8

Asymptomatic ICAS

For stroke-free individuals with asymptomatic ICAS:

• Vascular risk factor control is the primary strategy 4
• Routine aspirin is NOT recommended for primary prevention 4
• Endovascular treatment is NOT recommended 4

Critical Pitfalls to Avoid

1. Do not use warfarin—it increases bleeding risk without benefit 3
2. Do not rush to endovascular therapy—medical management must be optimized first and given adequate time 1, 6
3. Do not perform endovascular intervention in the acute phase (<21 days post-stroke)—this significantly increases procedural risk 4
4. Do not assume all stenosis is atherosclerotic—vessel wall imaging can help distinguish other etiologies, particularly in young patients 4

Monitoring and Follow-up

• Structured follow-up is essential to enhance treatment adherence 4
• Surveillance imaging may be needed as ICAS progression is common and associated with recurrent strokes 5
• Be prepared for urgent retreatment if acute reocclusion occurs after any intervention 8